External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

Equity Bottom-Up

<ul><li>SCHOTT Pharma AG &amp; Co. KGaA is experiencing accelerating growth in the pharmaceutical packaging industry due to the increasing prevalence of biologics, GLP-1s, and high value solutions.</li><li>The company's HVS segment is driving double-digit revenue growth and is expected to account for a larger percentage of total revenues in the future.</li><li>With solid pricing power in an oligopolistic industry, SCHOTT Pharma is well-positioned to benefit from the success of GLP-1s and further expand its market share.</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

SCHOTT Pharma AG &amp; Co. KGaA is experiencing accelerating growth in the pharmaceutical packaging industry due to the increasing prevalence of biologics, GLP-1s, and high value solutions.The company's HVS segment is driving double-digit revenue growth and is expected to account for a larger percentage of total revenues in the future.With solid pricing power in an oligopolistic industry, SCHOTT Pharma is well-positioned to benefit from the success of GLP-1s and further expand its market share.This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Schott Pharma Ag &Amp; Co. Kgaa  (1SXP GR) - Friday, Jan 26, 2024

Equity Analyst, Event-driven, Quiddity Advisors

Janaghan Jeyakumar, CFA

Equity Analyst, Event-driven

Quiddity Advisors

Pan-Asia Catalysts/Events

Event-Driven

<ul>
<li>In this insight, we take a look at the potential ADDs/DELs for the DAX index and the MDAX index in the run up to the June 2024 index rebal event.</li>
<li>I currently see no changes for the DAX index but there could be one change for the MDAX index.</li>
<li>M&amp;A candidate <a href="https://www.smartkarma.com/entities/morphosys-ag" target="_blank" data-smartkarma-citation="entities:21675:1" rel="noopener">MorphoSys AG (MOR GR)</a> could be deleted in the run up to the June 2024 review.</li>
</ul>


In this insight, we take a look at the potential ADDs/DELs for the DAX index and the MDAX index in the run up to the June 2024 index rebal event.
I currently see no changes for the DAX index but there could be one change for the MDAX index.
M&amp;A candidate MorphoSys AG (MOR GR) could be deleted in the run up to the June 2024 review.


Quiddity Leaderboard DAX/MDAX Mar 24: Traton Could Outperform the DAX Index

Germany

SCHOTT Pharma AG & Co. KGaA provides drug containment and drug delivery solutions. The Company offers prefillable syringes, cartridges, vials, and ampoules to analytical, development, fill-and-finish, and regulatory services for pharmaceutical companies, biotechs, and CDMOs. SCHOTT Pharma serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Schott Pharma (1SXP GR)

Schott Pharma Ag &Amp; Co. Kgaa (1SXP GR) - Friday, Jan 26, 2024

With solid pricing power in an oligopolistic industry, SCHOTT Pharma is well-positioned to benefit from the success of GLP-1s and further expand...

Value Investors Club

Quiddity Leaderboard DAX/MDAX Mar 24: Traton Could Outperform the DAX Index

Commercial vehicle manufacturer Traton is a strong candidate for MDAX addition. The expected index flow could act as a catalyst and help the stock...

Janaghan Jeyakumar, CFA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)